Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K37
- Development stage
- Preclinical
- Lead developer
- Bened Biomedical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
K37 is a specific strain of Lactobacillus plantarum developed by Bened Biomedical, a Taiwan-based company specializing in psychobiotic and probiotic research. It is primarily investigated for its immunomodulatory properties, specifically for the management of asthma and allergic responses. K37 functions by alleviating airway hyper-responsiveness and regulating T-helper cell immune reactions, specifically by strengthening Type 1 (Th1) and attenuating Type 2 (Th2) responses. Mechanistically, it has been shown to reduce serum levels of Immunoglobulin E (IgE) and modulate the expression of B-cells, T-cells, and pattern recognition receptors including Toll-like receptor 4 (TLR-4), Nucleotide-binding oligomerization domain-containing protein 1 (NOD-1), and Nucleotide-binding oligomerization domain-containing protein 2 (NOD-2). The strain is effective in both its live and heat-killed forms, positioning it as a versatile microbial therapy for immune-mediated inflammatory conditions.
- Brand names
- K37K-37K 37
- Other names
- Lactobacillus plantarum K37L. plantarum K37
02
Targets
NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)NOD1 (Nucleotide-binding oligomerization domain-containing protein 1)IgE (Immunoglobulin E)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on K37.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K37.